Moderna
US mRNA vaccine company; running first-ever Phase 3 H5N1 mRNA trial as of April 2026.
Last refreshed: 7 May 2026 · Appears in 1 active topic
If H5N1 jumps to humans at scale, how fast can Moderna's mRNA platform deliver a strain-matched vaccine?
Timeline for Moderna
Moderna begins Phase 3 H5N1 mRNA trial
Pandemics and Biosecurity- Is Moderna making an H5N1 bird flu vaccine?
- Yes. Moderna began the first Phase 3 trial of an mRNA H5N1 vaccine candidate in April 2026, backed by CEPI, making it the furthest-advanced H5N1 mRNA vaccine in clinical development.Source: CEPI
- How quickly can Moderna update its mRNA vaccine for a new pandemic strain?
- Moderna's mRNA platform can update its vaccine template in weeks once the target antigen sequence is known, compared to months for egg-based or protein-subunit conventional vaccines.
- What is Moderna's mRNA-1273 vaccine and when was it approved?
- mRNA-1273 (Spikevax) is Moderna's COVID-19 vaccine, authorised in late 2020. It was the first large-scale demonstration that mRNA vaccines could be developed, manufactured and deployed at population scale.
- Why does the H5N1 Phase 3 trial matter for pandemic preparedness?
- A successful trial establishes a regulatory-approved H5N1 mRNA manufacturing pathway. If a pandemic H5N1 strain emerges, Moderna can update the antigen and roll out a strain-matched vaccine FAR faster than starting from scratch.Source: CEPI
Background
Moderna is a US biotechnology company founded in 2010 in Cambridge, Massachusetts, specialising in messenger RNA (mRNA) therapeutics and vaccines. It became one of the two companies (alongside Pfizer-BioNTech) to bring an authorised mRNA COVID-19 vaccine to market in late 2020, validating the mRNA platform at population scale for the first time. Moderna's approach uses synthetic mRNA sequences to instruct cells to produce a target protein, triggering an immune response without using live or attenuated virus. The platform's key pandemic-preparedness advantage is speed: once a pathogen's target antigen sequence is known, Moderna can update its mRNA vaccine template in weeks rather than the months required by egg-based or protein-subunit approaches. The company is publicly traded (Nasdaq: mRNA).
Moderna began the first Phase 3 trial of an mRNA-based H5N1 vaccine candidate in April 2026, announced by CEPI on 22 April. This is the furthest any H5N1 mRNA candidate has reached in clinical development globally. The trial is the most advanced realisation of CEPI's 100 Days Mission: building immune infrastructure on the H5N1 antigen now, so that a strain-matched update can be authorised rapidly if an H5N1 pandemic variant emerges from the current US dairy or Bangladesh/Cambodia poultry reservoirs. Phase 3 data will be essential for any pre-pandemic authorisation or rapid emergency-use pathway.
